Dasatinib and the Risk of Pulmonary Arterial Hypertension

Published Online: Friday, October 21, 2011
Follow Pharmacy_Times:
In this podcast, Jennifer Shepherd, a pharmacist in the FDA’s Division of Drug Information, discusses the increased risk of pulmonary arterial hypertension associated with Sprycel (dasatinib), a drug indicated to treat leukemia.

To access the podcast, click here.
Related Articles
Many pharmacists dedicate themselves to improving the health of their patients and communities, but some answer an additional call: to provide their skills and knowledge in service to the military.
Established through a partnership of Parata Systems and Pharmacy Times, the Next-Generation Pharmacistâ„¢ program salutes pharmacy professionals in a variety of industry categories who are defining the future of pharmacy.
The possibilities to promote the pharmacy profession are limitless.
As pharmacy schools graduate more and more pharmacists, the next 20 years of the pharmacy profession could see job placement challenges.
Latest Issues
$auto_registration$